Dr. Julia C. Owens is the founding President & CEO of Millendo Therapeutics. She has an extensive background in venture-backed biopharmaceutical companies and particular expertise in pharmaceutical company transactions. Prior to co-founding Millendo in 2012, she served as senior vice president, corporate development and strategy at Lycera Corp., where she led the partnering process that led to Lycera’s major research partnerships with Merck & Co. Prior to Lycera, Dr. Owens served as head of business development at QuatRx Pharmaceuticals for six years. There, she established several key partnerships, including one with Shionogi for the approved drug, Osphena®. Earlier in her career, Dr. Owens worked at Tularik Inc. (now Amgen San Francisco) in business development for five years, where she led partnering for the oncology and immunology areas, as well as chaired the company’s technology acquisition efforts. Dr. Owens began her business career at the University of California, San Francisco Office of Technology Management.
Dr. Owens holds a Ph.D. in biochemistry from the University of California, San Francisco and a B.S. in chemistry and B.A. in molecular and cellular biology from the University of California, Berkeley.